GSK side-lines COVID drug otilimab to focus on XevudyGlaxoSmithKline said today it would halt further development of its antibody for severe COVID-19 pneumonia – otilimab – Share XGSK side-lines COVID drug otilimab to focus on Xevudyhttps://pharmaphorum.com/news/gsk-side-lines-covid-drug-otilimab-to-focus-on-xevudy/
Pair of R&D updates bolster GSK ahead of investor meetingGlaxoSmithKline (GSK) has reported encouraging data for its COVID-19 antibody sotrovimab, and an alliance with Halozyme to develop Share XPair of R&D updates bolster GSK ahead of investor meetinghttps://pharmaphorum.com/news/pair-of-rd-updates-bolster-gsk-ahead-of-investor-meeting/
EU starts rolling review of GSK’s antibody for COVID-19The EMA has begun a rolling review of a COVID-19 antibody developed by GlaxoSmithKline and Vir BioTech which Share XEU starts rolling review of GSK’s antibody for COVID-19https://pharmaphorum.com/news/eu-starts-rolling-review-of-gsks-antibody-for-covid-19/
EMA starts review of GSK/Vir COVID-19 antibodyThe EMA has started reviewing the emergency use application for GlaxoSmithKline and Vir Biotech’s COVID-19 antibody VIR-7831, which Share XEMA starts review of GSK/Vir COVID-19 antibodyhttps://pharmaphorum.com/news/ema-starts-review-of-gsk-vir-covid-19-antibody/
Lilly and GSK/Vir antibody pairing offers resistant COVID-19 hopeTwo antibodies targeting different parts of the COVID-19 virus spike protein, from Eli Lilly and GlaxoSmithKline/Vir Biotech, can Share XLilly and GSK/Vir antibody pairing offers resistant COVID-19 hopehttps://pharmaphorum.com/news/lilly-and-gsk-vir-antibody-pairing-offers-resistant-covid-19-hope/
GSK and Vir expand COVID-19 antibody trial after Trump’s treatment with Regeneron’s rivalGlaxoSmithKline and partner Vir Biotechnology are to expand a trial of an experimental antibody to treat COVID-19, putting Share XGSK and Vir expand COVID-19 antibody trial after Trump’s treatment with Regeneron’s rivalhttps://pharmaphorum.com/news/gsk-and-vir-expand-covid-19-antibody-trial-after-trumps-treatment-with-regenerons-rival/
GSK and Vir take COVID-19 antibody therapy into clinicGlaxoSmithKline and US-based Vir Biotechnology are to trial a new therapy for COVID-19 based on an antibody designed Share XGSK and Vir take COVID-19 antibody therapy into clinichttps://pharmaphorum.com/news/gsk-and-vir-take-covid-19-antibody-therapy-into-clinic/
